远端胰腺切除术瘘风险评分的国际验证:微创与开放手术评估
这项国际多中心回顾性队列研究在12个中心778例远端胰腺切除患者中外部验证术前D-FRS对POPF的预测效能,总体AUC仅48%(95%CI 44-51%),不同手术方式AUC均低,提示判别能力不足。多因素分析显示BMI与POPF相关,新辅助治疗和机器人入路为保护因素。
要点
- D-FRS在整体队列中AUC为48%(95%CI 44-51%),判别能力不足。
- 开放、腹腔镜和机器人DP的AUC分别为54%、47%和45%,均较低。
- BMI与POPF相关,新辅助治疗和机器人入路为保护因素。
核心结论
- 术前D-FRS对远端胰腺切除术后POPF的判别能力不足,无论手术方式如何。
研究设计与样本
- 国际多中心回顾性队列研究,纳入2014年1月至2023年12月6国12个中心778例远端胰腺切除患者。
主要发现
- 总体POPF发生率为32%。
- D-FRS总体敏感度32%、特异度63%、AUC 48%(95%CI 44-51%)。
- 开放、腹腔镜和机器人DP的AUC分别为54%(48-60%)、47%(39-55%)和45%(39-50%)。
- 新辅助治疗初治患者AUC为52.3%。
- 多因素分析POPF与BMI相关(OR 1.04,95%CI 1.01-1.07),新辅助治疗(OR 0.54,95%CI 0.22-0.94)和机器人入路(OR 0.64,95%CI 0.42-0.97)为保护因素。
临床怎么用
- D-FRS目前不适用于常规术前POPF风险分层,需谨慎解读。
- 临床决策应综合考虑BMI、新辅助治疗和手术入路等因素。
局限性
- 回顾性设计可能引入偏倚。
- D-FRS计算仅基于胰腺厚度和胰管直径,未涵盖其他风险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative pancreatic fistula (POPF) remains the most severe complication following distal pancreatectomy (DP). The preoperative distal fistula risk score (D-FRS) was introduced to predict the POPF risk. The aim of this study was to externally validate the D-FRS in an international expert center cohort. METHODS: This international, multicenter, retrospective cohort study included open and minimally invasive DP for benign and malignant lesions performed from 01/2014 until 12/2023 in 12 centres from 6 countries, that each performed more than 50 pancreatectomies annually. The D-FRS was calculated from pancreatic thickness and duct size. Predicted and actual POPF were compared using sensitivity, specificity and area under the curve (AUC). RESULTS: A total of 778 patients underwent DP of whom 284 (39%) underwent robotic, 278 (38%) open and 165 (23%) laparoscopic DP. The rate of POPF was 32%. The sensitivity, specificity and AUC of the D-FRS for the overall cohort was 32%, 63% and 48% (95% CI 44-51%), respectively. The AUC for open, laparoscopic and robotic DP was 54% (48-60%), 47% (39-55%) and 45% (39-50%), respectively. For neoadjuvant therapy naïve patients the AUC was 52.3%. On multivariate analysis POPF was associated with body mass index (odds ratio 1.04 (95% CI 1.01-1.07)), protective factors were neoadjuvant therapy (OR 0.54 (0.22-0.94)) and the robotic approach (OR 0.64 (0.42-0.97)). CONCLUSIONS: The preoperative D-FRS showed insufficient discrimination to identify patients who develop POPF after DP irrespective of the surgical approach. Novel preoperative POPF risk scores are needed, considering the standard minimally invasive approach and the widespread use of neoadjuvant therapy.
引用
- Müller PC, Erdem S, Kuemmerli C, et al. International validation of the distal pancreatectomy fistula risk score: evaluation in minimally invasive and open surgery. Surg Endosc. 2025. PMID: 40542140. doi:10.1007/s00464-025-11872-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。